{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T01:34:07Z","timestamp":1784770447602,"version":"3.55.0"},"reference-count":63,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The management of urothelial carcinoma (UC) is undergoing a paradigm shift from static anatomical staging to molecularly guided dynamic approaches that integrate time as a critical therapeutic variable. This evolution is driven by liquid biopsies, particularly circulating tumor DNA, which allow real-time tumor interrogation. We conducted this expert review to synthesize landmark evidence, enabling technologies, and implementation challenges in dynamic precision oncology for UC. In this non-systematic narrative review, we searched PubMed\/MEDLINE, Embase, Web of Science, and the Cochrane Library for articles published between January 2015 and February 2026. Studies were selected based on their relevance to dynamic precision oncology, clinical actionability, and translational implementation, prioritizing landmark randomized controlled trials providing level 1\u20132 evidence, large prospective cohorts, and key translational studies. Enfortumab vedotin plus pembrolizumab established the new first-line standard for metastatic UC, achieving a median overall survival of 33.8 months versus 15.9 months (hazard ratio [HR] 0.51, 95% confidence interval 0.43\u20130.61). Circulating tumor DNA demonstrates robust prognostic value for molecular residual disease (MRD) detection (Level 2a evidence), stratifying recurrence risk with hazard ratios of approximately 4.5. Critically, the IMvigor011 trial has now provided Level 1b evidence that ctDNA-guided adjuvant atezolizumab improves both disease-free survival (DFS) (HR 0.64, p = 0.0047) and OS (HR 0.59, p = 0.0131) in ctDNA(+) patients, while validating treatment de-escalation in ctDNA(\u2212) patients (1-year DFS 95%). Erdafitinib in patients harboring FGFR2\/3 alterations (HR 0.64) confirms the value of genomic profiling. Major limitations include the inherent selection bias of this non-systematic approach, substantial platform heterogeneity, and lack of standardization. In conclusion, dynamic precision oncology has transformed UC management, with the IMvigor011 trial establishing ctDNA-guided MRD status as the first phase 3-validated predictive biomarker framework for adjuvant therapy selection in a solid tumor. Implementation requires adherence to established standardization frameworks, cross-platform and cross-agent validations, and tiered implementation strategies to ensure equitable access across diverse resource settings.<\/jats:p>","DOI":"10.3390\/ijms27083474","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T10:19:14Z","timestamp":1776075554000},"page":"3474","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dynamic Precision Oncology for Real-Time Molecular Monitoring and Management in Urothelial Carcinoma"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7833-5981","authenticated-orcid":false,"given":"Whi-An","family":"Kwon","sequence":"first","affiliation":[{"name":"Department of Urology, Hanyang University College of Medicine, Myongji Hospital, Goyang 10475, Republic of Korea"},{"name":"Research Institute of Precision Medicine and Geroscience, Myongji Medical Foundation, Goyang 10475, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6652-5139","authenticated-orcid":false,"given":"Yeon Jee","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Hanyang University College of Medicine, Myongji Hospital, Goyang 10475, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7115-4021","authenticated-orcid":false,"given":"Yong Sang","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Hanyang University College of Medicine, Myongji Hospital, Goyang 10475, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"216","DOI":"10.6004\/jnccn.2024.0024","article-title":"NCCN Guidelines\u00ae insights: Bladder cancer, version 3.2024","volume":"22","author":"Flaig","year":"2024","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41586-024-07955-3","article-title":"The interplay of mutagenesis and ecDNA shapes urothelial cancer evolution","volume":"635","author":"Nguyen","year":"2024","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1038\/s42003-023-05668-3","article-title":"Transcriptional state dynamics lead to heterogeneity and adaptive tumor evolution in urothelial bladder carcinoma","volume":"6","author":"Biswas","year":"2023","journal-title":"Commun. Biol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1038\/s41467-024-46320-w","article-title":"The evolution of metastatic upper tract urothelial carcinoma through genomic-transcriptomic and single-cell protein markers analysis","volume":"15","author":"Ohara","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"14586","DOI":"10.1073\/pnas.1203559109","article-title":"Impact of genetic dynamics and single-cell heterogeneity on development of nonstandard personalized medicine strategies for cancer","volume":"109","author":"Beckman","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e2300714","DOI":"10.1200\/PO.23.00714","article-title":"Generalized evolutionary classifier for evolutionary guided precision medicine","volume":"9","author":"McCoy","year":"2025","journal-title":"JCO Precis. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1038\/s41591-025-03579-w","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial","volume":"31","author":"Tie","year":"2025","journal-title":"Nat. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa2511885","article-title":"ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer","volume":"393","author":"Powles","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/s41585-023-00725-2","article-title":"Circulating and urinary tumour DNA in urothelial carcinoma\u2014Upper tract, lower tract and metastatic disease","volume":"20","author":"Rose","year":"2023","journal-title":"Nat. Rev. Urol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1038\/s41591-025-03802-8","article-title":"Adjuvant nivolumab in muscle-invasive urothelial carcinoma: Exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial","volume":"31","author":"Galsky","year":"2025","journal-title":"Nat. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.eururo.2023.06.007","article-title":"Updated overall survival by circulating tumor DNA status from the phase 3 IMvigor010 trial: Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"85","author":"Powles","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: The ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41698-025-00876-y","article-title":"Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology","volume":"9","author":"Bartolomucci","year":"2025","journal-title":"NPJ Precis. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s41392-024-02021-w","article-title":"Liquid biopsy in cancer: Current status, challenges and future prospects","volume":"9","author":"Ma","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.annonc.2025.09.139","article-title":"Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274","volume":"37","author":"Galsky","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.annonc.2025.05.536","article-title":"Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302\/KEYNOTE-A39 trial","volume":"36","author":"Powles","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"Sonpavde","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.24.00340","article-title":"Adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma: Expanded efficacy from CheckMate 274","volume":"43","author":"Galsky","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.eururo.2024.10.014","article-title":"Sensitive detection of urothelial cancer via high-volume urine DNA analysis","volume":"87","author":"Nikkola","year":"2025","journal-title":"Eur. Urol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1002\/1878-0261.13639","article-title":"Distinct longitudinal patterns of urine tumor DNA in patients undergoing surveillance for bladder cancer","volume":"18","author":"Vedeld","year":"2024","journal-title":"Mol. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/JU.0000000000001878","article-title":"Urinary molecular pathology for patients with newly diagnosed urothelial bladder cancer","volume":"206","author":"Zhang","year":"2021","journal-title":"J. Urol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.euo.2022.03.005","article-title":"Highly sensitive and specific detection of bladder cancer via targeted ultra-deep sequencing of urinary DNA","volume":"6","author":"Ward","year":"2023","journal-title":"Eur. Urol. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1158\/1078-0432.CCR-23-0570","article-title":"Development and multicenter case-control validation of urinary comprehensive genomic profiling for urothelial carcinoma diagnosis, surveillance, and risk-prediction","volume":"29","author":"Salari","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/2159-8290.CD-14-0623","article-title":"Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma","volume":"4","author":"Mouw","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1200\/JCO-24-01214","article-title":"Phase II trial of risk-enabled therapy after neoadjuvant chemotherapy for muscle-invasive bladder cancer (RETAIN 1)","volume":"43","author":"Geynisman","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1158\/1078-0432.CCR-22-3250","article-title":"Cell-free urine and plasma DNA mutational analysis predicts neoadjuvant chemotherapy response and outcome in patients with muscle-invasive bladder cancer","volume":"29","author":"Christensen","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e2533449123","DOI":"10.1073\/pnas.2533449123","article-title":"Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer","volume":"123","author":"Galsky","year":"2026","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.eururo.2024.05.014","article-title":"Whole-genome mutational analysis for tumor-informed detection of circulating tumor DNA in patients with urothelial carcinoma","volume":"86","author":"Nordentoft","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.21037\/tau-24-7","article-title":"Towards circulating tumor DNA-guided treatment of muscle-invasive bladder cancer","volume":"13","author":"Lindskrog","year":"2024","journal-title":"Transl. Androl. Urol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1158\/2159-8290.CD-22-1441","article-title":"Resistance to selective FGFR inhibitors in FGFR-driven urothelial cancer","volume":"13","author":"Facchinetti","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"105544","DOI":"10.1016\/j.esmoop.2025.105544","article-title":"Exploratory subgroup analyses of EV-302: A phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma","volume":"10","author":"Powles","year":"2025","journal-title":"ESMO Open"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"102900","DOI":"10.1016\/j.ctrv.2025.102900","article-title":"Individualizing first-line treatment for advanced urothelial carcinoma: A favorable dilemma for patients and physicians","volume":"134","author":"Grande","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","article-title":"Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): A multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Bellmunt","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e320","DOI":"10.3346\/jkms.2024.39.e320","article-title":"FGFR inhibitors in urothelial cancer: From scientific rationale to clinical development","volume":"39","author":"Kwon","year":"2024","journal-title":"J. Korean Med. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Zhou, Y., Wang, R., Zeng, M., and Liu, S. (2025). Circulating tumor DNA: A revolutionary approach for early detection and personalized treatment of bladder cancer. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1551219"},{"key":"ref_39","unstructured":"US Food and Drug Administration (2025, October 06). FDA Grants Accelerated Approval to Fam-Trastuzumab Deruxtecan-Nxki for Unresectable or Metastatic HER2-Positive Solid Tumors, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: Primary results from the DESTINY-PanTumor02 Phase II trial","volume":"42","author":"Makker","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12935-025-03707-z","article-title":"Prognostic and predictive role of circulating tumor DNA detection in patients with muscle invasive bladder cancer: A systematic review and meta-analysis","volume":"25","author":"Gao","year":"2025","journal-title":"Cancer Cell Int."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1158\/2159-8290.CD-21-0634","article-title":"Detecting liquid remnants of solid tumors: Circulating tumor DNA minimal residual disease","volume":"11","author":"Moding","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Chan, H.T., Nagayama, S., Otaki, M., Chin, Y.M., Fukunaga, Y., Ueno, M., Nakamura, Y., and Low, S.-K. (2023). Tumor-informed or tumor-agnostic circulating tumor DNA as a biomarker for risk of recurrence in resected colorectal cancer patients. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1055968"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s40364-025-00796-w","article-title":"Circulating tumor DNA for MRD detection in colorectal cancer: Recent advances and clinical implications","volume":"13","author":"Ma","year":"2025","journal-title":"Biomark. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"oyaf204","DOI":"10.1093\/oncolo\/oyaf204","article-title":"Circulating Tumor DNA detection in cancer: A comprehensive overview of current detection methods and prospects","volume":"30","author":"Wyninckx","year":"2025","journal-title":"Oncologist"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1038\/s41375-020-0869-y","article-title":"Prevalence and dynamics of clonal hematopoiesis caused by leukemia-associated mutations in elderly individuals without hematologic disorders","volume":"34","author":"Midic","year":"2020","journal-title":"Leukemia"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1158\/1078-0432.CCR-24-3335","article-title":"Characterization of plasma cell-free DNA variants as of tumor or clonal hematopoiesis origin in 16,812 advanced cancer patients","volume":"31","author":"Magee","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: A report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.euo.2024.09.016","article-title":"Minimal residual disease detection with urine-derived DNA is prognostic for recurrence-free survival in Bacillus Calmette-Gu\u00e9rin-unresponsive non-muscle-invasive bladder cancer treated with Nadofaragene Firadenovec","volume":"8","author":"Narayan","year":"2025","journal-title":"Eur. Urol. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.annonc.2023.10.003","article-title":"Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: Cohort 2 of the randomized phase III Thor trial","volume":"35","author":"Matsubara","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/s41591-024-03040-4","article-title":"Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichment","volume":"30","author":"Widman","year":"2024","journal-title":"Nat. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41551-025-01370-3","article-title":"A deep-learning model for quantifying circulating tumour DNA from the density distribution of DNA-fragment lengths","volume":"9","author":"Zhu","year":"2025","journal-title":"Nat. Biomed. Eng."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"8801","DOI":"10.1038\/s41467-024-53017-7","article-title":"Cancer treatment monitoring using cell-free DNA fragmentomes","volume":"15","author":"Alipanahi","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/s41698-025-01130-1","article-title":"Early detection of urological tumors based on genomic characteristics of cell-free DNA fragments: A multi-center study","volume":"9","author":"Zhang","year":"2025","journal-title":"npj Precis. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41746-025-01560-y","article-title":"Predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer via interpretable multimodal deep learning","volume":"8","author":"Bai","year":"2025","journal-title":"npj Digit. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jmoldx.2023.09.004","article-title":"Recommendations for cell-free DNA assay validations: A joint consensus recommendation of the association for molecular pathology and College of American Pathologists","volume":"25","author":"Lockwood","year":"2023","journal-title":"J. Mol. Diagn."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e2500267","DOI":"10.1200\/PO-25-00267","article-title":"Generic protocols for analytical validation of tumor-informed circulating tumor DNA assays for molecular residual disease: The blood profiling atlas in Cancer\u2019s molecular residual disease analytical validation working group consensus recommendation","volume":"10","author":"Baden","year":"2026","journal-title":"JCO Precis. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"100301","DOI":"10.1016\/j.jlb.2025.100301","article-title":"International society of liquid biopsy (ISLB) perspective on minimal requirements for ctDNA testing in solid tumors","volume":"8","author":"Fusco","year":"2025","journal-title":"J. Liq. Biopsy"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.annonc.2023.12.007","article-title":"Liquid biopsy response evaluation criteria in solid tumors (LB-RECIST)","volume":"35","author":"Gouda","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"105760","DOI":"10.1016\/j.esmoop.2025.105760","article-title":"Clinical validation of liquid biopsy-RECIST (LB-RECIST) in metastatic colorectal cancer (mCRC) patients: Findings from the PLATFORM-B study","volume":"10","author":"Martelli","year":"2025","journal-title":"ESMO Open"},{"key":"ref_62","unstructured":"US Food and Drug Administration (2026, March 28). Use of Circulating Tumor Deoxyribonucleic Acid for Early-Stage Solid Tumor Drug Development: Guidance for Industry, Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/use-circulating-tumor-deoxyribonucleic-acid-early-stage-solid-tumor-drug-development-guidance."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/PAI.0000000000000938","article-title":"Expression of Nectin-4 in bladder urothelial carcinoma, in morphologic variants, and nonurothelial histotypes","volume":"29","author":"Lombardo","year":"2021","journal-title":"Appl. Immunohistochem. Mol. Morphol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/8\/3474\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T10:20:44Z","timestamp":1776075644000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/8\/3474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":63,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["ijms27083474"],"URL":"https:\/\/doi.org\/10.3390\/ijms27083474","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]}}}